Researchers at Cleveland Clinic are taking part in a clinical trial that could lead to the development of a blood test for early-stage cancer. This study, in partnership with GRAIL, Inc., will analyze cell-free nucleic acids in the blood to help detect cancer earlier. This year at the 2017 Medical Innovation Summit, GRAIL Chief Business Officer, Ken Drazan, will speak on the panel "Breaking the Code: Will Next-Generation Sequencing Bring Genomics to The Mainstream?" with other experts in the field. To learn more about this clinical trial, read the full article on ConsultQD.